WASHINGTON, May 6 (Reuters) - A U.S. Food and Drug Administration advisory panel on Thursday:
* said Questcor Pharmaceutical Inc's has provided substantial
evidence for its Acthar Gel to treat infantile spasms
* voted 22-1 in backing effectiveness of ACthar's infant use
* FDA panel must still discuss drugs safety, whether further studies needed
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* said Questcor Pharmaceutical Inc's has provided substantial
evidence for its Acthar Gel to treat infantile spasms
* voted 22-1 in backing effectiveness of ACthar's infant use
* FDA panel must still discuss drugs safety, whether further studies needed
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.